UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Annals of oncology, 2017-04, Vol.28 (4), p.874-881

2017

Volltextzugriff (PDF)

A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort

Annals of oncology, 2018-10, Vol.29, p.viii344-viii344

2018

Volltextzugriff (PDF)

195TiP Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S142-S142

2016

Volltextzugriff (PDF)

Adverse event profile by folate receptor status for vintafolide + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer

Gynecologic oncology, 2014-06, Vol.133, p.178-178

2014

Volltextzugriff (PDF)

CA-125 as a response marker for vintafolide + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: The PRECEDENT trial

Gynecologic oncology, 2014-06, Vol.133, p.177-178

2014

Volltextzugriff (PDF)

33LBA Efficacy and Safety of Pembrolizumab (Pembro; MK-3475) for Patients (Pts) With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Enrolled in KEYNOTE-001

European journal of cancer (1990), 2015-09, Vol.51, p.S726-S727

2015

Volltextzugriff (PDF)

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

The lancet oncology, 2021-05, Vol.22 (5), p.609-619

2021

Volltextzugriff (PDF)

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

The lancet oncology, 2019-03, Vol.20 (3), p.383-393

2019

Volltextzugriff (PDF)

LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study

Annals of oncology, 2020-09, Vol.31, p.S1162-S1163

2020

Volltextzugriff (PDF)

481TiP Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ non-small cell lung cancer (NSCLC): Randomized, open-label, phase 3 KEYNOTE-042 study

Annals of oncology, 2015-12, Vol.26, p.ix125-ix125

2015

Volltextzugriff (PDF)

Coordinate control of axon defasciculation and myelination by laminin-2 and -8

The Journal of cell biology, 2005-02, Vol.168 (4), p.655-666

2005

Volltextzugriff (PDF)

963PA phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024

Annals of oncology, 2016-10, Vol.27, p.vi363-vi363

2016

Volltextzugriff (PDF)

KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50

Annals of oncology, 2016-10, Vol.27, p.vi578-vi578

2016

Volltextzugriff (PDF)

Erbin Regulates Mitogen-activated Protein (MAP) Kinase Activation and MAP Kinase-dependent Interactions between Merlin and Adherens Junction Protein Complexes in Schwann Cells

The Journal of biological chemistry, 2005-03, Vol.280 (12), p.11790-11797

2005

Volltextzugriff (PDF)

437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 50

Annals of oncology, 2016-12, Vol.27, p.ix139-ix139

2016

Volltextzugriff (PDF)

437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

Regulation of Immunoproteasome Subunit Expression In Vivo Following Pathogenic Fungal Infection

The Journal of immunology (1950), 2002-09, Vol.169 (6), p.3046-3052

2002

Volltextzugriff (PDF)

Hyaluronate-based extracellular matrix: Keeping glia in their place

Glia, 2002-04, Vol.38 (2), p.93-102

2002

Volltextzugriff (PDF)

CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells

Applied immunohistochemistry & molecular morphology, 2002-03, Vol.10 (1), p.34

2002

Volltextzugriff (PDF)

Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042: 195TiP

Journal of thoracic oncology, 2016-04, Vol.11 (4 Suppl), p.S142-S142

2016

Volltextzugriff (PDF)

Database resources of the National Center for Biotechnology Information

Nucleic acids research, 2021-01, Vol.49 (D1), p.D10-D17

2021

Volltextzugriff (PDF)

Climate change in mountains: a review of elevation-dependent warming and its possible causes

Climatic change, 2012-10, Vol.114 (3-4), p.527-547

2012

Volltextzugriff (PDF)

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2016-11, Vol.375 (19), p.1823-1833

2016

Volltextzugriff (PDF)

GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates

Nature medicine, 2017-10, Vol.23 (10), p.1150-1157

2017

Volltextzugriff (PDF)

1 – 25 von 262

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(217)
Mit Volltextzugriff
(218)

Publikationsform

Sprache

Englisch
(262)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort

195TiP Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042

Adverse event profile by folate receptor status for vintafolide + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer

CA-125 as a response marker for vintafolide + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: The PRECEDENT trial

33LBA Efficacy and Safety of Pembrolizumab (Pembro; MK-3475) for Patients (Pts) With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Enrolled in KEYNOTE-001

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study

481TiP Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ non-small cell lung cancer (NSCLC): Randomized, open-label, phase 3 KEYNOTE-042 study

Coordinate control of axon defasciculation and myelination by laminin-2 and -8

963PA phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort

Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024

KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50

Erbin Regulates Mitogen-activated Protein (MAP) Kinase Activation and MAP Kinase-dependent Interactions between Merlin and Adherens Junction Protein Complexes in Schwann Cells

437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 50

437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50

Regulation of Immunoproteasome Subunit Expression In Vivo Following Pathogenic Fungal Infection

Hyaluronate-based extracellular matrix: Keeping glia in their place

CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells

Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042: 195TiP

Database resources of the National Center for Biotechnology Information

Climate change in mountains: a review of elevation-dependent warming and its possible causes

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates

Suchergebnisse filtern